StemRIM
Notice on Issuance of Stock Options (Stock Acquisition Rights) to Our Directors
Stock options granted to four directors. Total of 3,000 units, 100 shares per unit, granted at no cost, exercise price is the closing price on the allocation date multiplied by 1.025, term of exercisability from 2028/9/11 to 2036/9/9, maximum dilution 0.47%, allocation date 2026/9/10, with details on exercise conditions and handling in case of reorganization.
Key Figures
- Number of stock options issued: 3,000 units
- Shares granted: 300,000 shares (100 shares per unit)
- Maximum dilution: 0.47%
- Exercise price: Allocation date closing price × 1.025, rounding up to the nearest yen
- Exercise period: September 11, 2028 – September 9, 2036
AI要約
Section Heading
This matter reports that resolutions were made to issue stock options to four directors of our company (including outside directors). Grants are free of charge, with 100 shares per unit and a total of 3,000 units. The exercise price is the allocation-day closing price multiplied by 1.025, with adjustment provisions for stock splits and reverse splits and provisions for adjustments at the time of equity issuance. The exercise period is from 2028/9/11 to 2036/9/9. The maximum dilution is expected to be 0.47%.
Section 2 Heading
The conditions for acquiring the stock options, transfer restrictions, handling during corporate reorganizations, acquisition grounds, and other exercise conditions and post-reorganization treatment are detailed. Regarding impact on shareholders, it is deemed within a reasonable range, and since the consideration is free, there will be no capital increase. The future impact on shareholder value will be evaluated as an emergent talent incentive design.
Stemrim Co., Ltd.
Company overview · Stock price · Financial data · All IR
